466 
cell therapeutic products as contained in 
the database established pursuant to sec-
tion 379A; and 
‘‘(v) any other factors pertaining to 
acquired bone marrow failure diseases de-
termined appropriate by the Secretary; and 
‘‘(C) shall be made available— 
‘‘(i) to the general public; and 
‘‘(ii) to researchers to facilitate fur-
ther research into the causes of, and treat-
ments for, acquired bone marrow failure 
diseases in accordance with standard prac-
tices of the Centers for Disease Control 
and Preventions. 
‘‘(b) ADVISORY COMMITTEE.— 
‘‘(1) ESTABLISHMENT.—Not later than 6 
months after the date of the enactment of this sec-
tion, the Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, 
shall establish an advisory committee, to be known 
as the Advisory Committee on Acquired Bone Mar-
row Failure Diseases. 
‘‘(2) MEMBERS.—The members of the Advisory 
Committee on Acquired Bone Marrow Failure Dis-
eases shall be appointed by the Secretary, acting 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00466
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
467 
through the Director of the Centers for Disease 
Control and Prevention, and shall include at least 
one representative from each of the following: 
‘‘(A) A national patient advocacy organiza-
tion with experience advocating on behalf of pa-
tients suffering from acquired bone marrow 
failure diseases. 
‘‘(B) The National Institutes of Health, in-
cluding at least one representative from each 
of— 
‘‘(i) the National Cancer Institute; 
‘‘(ii) the National Heart, Lung, and 
Blood Institute; and 
‘‘(iii) the Office of Rare Diseases. 
‘‘(C) The Centers for Disease Control and 
Prevention. 
‘‘(D) Clinicians with experience in— 
‘‘(i) diagnosing or treating acquired 
bone marrow failure diseases; and 
‘‘(ii) medical data registries. 
‘‘(E) Epidemiologists who have experience 
with data registries. 
‘‘(F) Publicly or privately funded research-
ers who have experience researching acquired 
bone marrow failure diseases. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00467
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
468 
‘‘(G) The entity operating the C.W. Bill 
Young Cell Transplantation Program estab-
lished pursuant to section 379 and the entity 
operating the C.W. Bill Young Cell Transplan-
tation Program Outcomes Database. 
‘‘(3) RESPONSIBILITIES.—The Advisory Com-
mittee on Acquired Bone Marrow Failure Diseases 
shall provide recommendations to the Secretary on 
the establishment and maintenance of the National 
Acquired Bone Marrow Failure Disease Registry, in-
cluding recommendations on the collection, mainte-
nance, and dissemination of data. 
‘‘(4) PUBLIC
AVAILABILITY.—The Secretary 
shall make the recommendations of the Advisory 
Committee on Acquired Bone Marrow Failure Dis-
ease publicly available. 
‘‘(c) GRANTS.—The Secretary, acting through the 
Director of the Centers for Disease Control and Preven-
tion, may award grants to, and enter into contracts and 
cooperative agreements with, public or private nonprofit 
entities for the management of, as well as the collection, 
analysis, and reporting of data to be included in, the Na-
tional Acquired Bone Marrow Failure Disease Registry. 
‘‘(d) DEFINITION.—In this section, the term ‘ac-
quired bone marrow failure disease’ means— 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00468
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
469 
‘‘(1) myelodysplastic syndromes (MDS); 
‘‘(2) aplastic anemia; 
‘‘(3) 
paroxysmal 
nocturnal 
hemoglobinuria 
(PNH); 
‘‘(4) pure red cell aplasia; 
‘‘(5) acute myeloid leukemia that has pro-
gressed from myelodysplastic syndromes; or 
‘‘(6) large granular lymphocytic leukemia. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
$3,000,000 for each of fiscal years 2015 through 2019.’’. 
(d) PILOT STUDIES THROUGH THE AGENCY FOR 
TOXIC SUBSTANCES AND DISEASE REGISTRY.— 
(1) PILOT STUDIES.—The Secretary of Health 
and Human Services, acting through the Adminis-
trator of the Agency for Toxic Substances and Dis-
ease Registry, shall conduct pilot studies to deter-
mine which environmental factors, including expo-
sure to toxins, may cause acquired bone marrow fail-
ure diseases. 
(2) COLLABORATION WITH THE RADIATION IN-
JURY TREATMENT NETWORK.—In carrying out the 
directives of this section, the Secretary may collabo-
rate with the Radiation Injury Treatment Network 
of the C.W. Bill Young Cell Transplantation Pro-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00469
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
470 
gram established pursuant to section 379 of the 
Public Health Service Act (42 U.S.C. 274j) to— 
(A) augment data for the pilot studies au-
thorized by this section; 
(B) access technical assistance that may be 
provided by the Radiation Injury Treatment 
Network; or 
(C) perform joint research projects. 
(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this section $1,000,000 for each of fiscal years 2015 
through 2019. 
(e) MINORITY-FOCUSED PROGRAMS ON ACQUIRED 
BONE MARROW FAILURE DISEASES.—Title XVII of the 
Public Health Service Act (42 U.S.C. 300u et seq.) is 
amended by inserting after section 1707A the following: 
‘‘MINORITY-FOCUSED PROGRAMS ON ACQUIRED BONE 
MARROW FAILURE DISEASES 
‘‘SEC. 1707B. (a) INFORMATION
AND REFERRAL 
SERVICES.— 
‘‘(1) IN GENERAL.—Not later than 6 months 
after the date of the enactment of this section, the 
Secretary, acting through the Deputy Assistant Sec-
retary for Minority Health, shall establish and co-
ordinate outreach and informational programs tar-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00470
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
471 
geted to minority populations affected by acquired 
bone marrow failure diseases. 
‘‘(2) PROGRAM
REQUIREMENTS.—Minority-fo-
cused outreach and informational programs author-
ized by this section— 
‘‘(A) shall make information about treat-
ment options and clinical trials for acquired 
bone marrow failure diseases publicly available, 
and 
‘‘(B) shall provide referral services for 
treatment options and clinical trials, 
at the National Minority Health Resource Center 
supported under section 1707(b)(8) (including by 
means of the Center’s Web site, through appropriate 
locations such as the Center’s knowledge center, and 
through appropriate programs such as the Center’s 
resource persons network) and through minority 
health consultants located at each Department of 
Health and Human Services regional office. 
‘‘(b) HISPANIC AND ASIAN-AMERICAN AND PACIFIC 
ISLANDER OUTREACH.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Deputy Assistant Secretary for Minority 
Health, shall undertake a coordinated outreach ef-
fort to connect Hispanic, Asian-American, and Pa-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00471
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
472 
cific Islander communities with comprehensive serv-
ices focused on treatment of, and information about, 
acquired bone marrow failure diseases. 
‘‘(2) COLLABORATION.—In carrying out this 
subsection, the Secretary may collaborate with public 
health agencies, nonprofit organizations, community 
groups, and online entities to disseminate informa-
tion about treatment options and clinical trials for 
acquired bone marrow failure diseases. 
‘‘(c) GRANTS AND COOPERATIVE AGREEMENTS.— 
‘‘(1) IN GENERAL.—Not later than 6 months 
after the date of the enactment of this section, the 
Secretary, acting through the Deputy Assistant Sec-
retary for Minority Health, shall award grants to, or 
enter into cooperative agreements with, entities to 
perform research on acquired bone marrow failure 
diseases. 
‘‘(2) REQUIREMENT.—Grants and cooperative 
agreements authorized by this subsection shall be 
awarded or entered into on a competitive, peer-re-
viewed basis. 
‘‘(3) SCOPE OF RESEARCH.—Research funded 
under this section shall examine factors affecting the 
incidence of acquired bone marrow failure diseases 
in minority populations. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00472
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
473 
‘‘(d) DEFINITION.—In this section, the term ‘ac-
quired bone marrow failure disease’ has the meaning given 
to such term in section 317X(d). 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
$2,000,000 for each of fiscal years 2015 through 2019.’’. 
(f) DIAGNOSIS
AND QUALITY
OF CARE
FOR AC-
QUIRED BONE MARROW FAILURE DISEASES.— 
(1) GRANTS.—The Secretary of Health and 
Human Services, acting through the Director of the 
Agency for Healthcare Research and Quality, shall 
award grants to entities to improve diagnostic prac-
tices and quality of care with respect to patients 
with acquired bone marrow failure diseases. 
(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this section $2,000,000 for each of fiscal years 2015 
through 2019. 
(g) DEFINITION.—In this section, the term ‘‘acquired 
bone marrow failure disease’’ means— 
(1) myelodysplastic syndromes (MDS); 
(2) aplastic anemia; 
(3) 
paroxysmal 
nocturnal 
hemoglobinuria 
(PNH); 
(4) pure red cell aplasia; 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00473
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
474 
(5) acute myeloid leukemia that progressed 
from myelodysplastic syndromes; or 
(6) large granular lymphocytic leukemia. 
Subtitle 
D—Cardiovascular 
Dis-
ease, 
Chronic 
Disease, 
and 
Other Disease Issues 
SEC. 731. GUIDELINES FOR DISEASE SCREENING FOR MI-
NORITY PATIENTS. 
(a) IN GENERAL.—The Secretary, acting through the 
Director of the Agency for Healthcare Research and Qual-
ity, shall convene a series of meetings to develop guidelines 
for disease screening for minority patient populations 
which have a higher than average risk for many chronic 
diseases and cancers. 
(b) PARTICIPANTS.—In convening meetings under 
subsection (a), the Secretary shall ensure that meeting 
participants include representatives of— 
(1) professional societies and associations; 
(2) minority health organizations; 
(3) health care researchers and providers, in-
cluding those with expertise in minority health; 
(4) Federal health agencies, including the Of-
fice of Minority Health, the National Institute on 
Minority Health and Health Disparities, and the 
National Institutes of Health; and 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00474
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
475 
(5) other experts determined appropriate by the 
Secretary. 
(c) DISEASES.—Screening guidelines for minority 
populations shall be developed as appropriate under sub-
section (a) for— 
(1) hypertension; 
(2) hypercholesterolemia; 
(3) diabetes; 
(4) cardiovascular disease; 
(5) cancers, including breast, prostate, colon, 
cervical, and lung cancer; 
(6) asthma; 
(7) diabetes; 
(8) kidney diseases; 
(9) eye diseases and disorders, including glau-
coma; 
(10) HIV/AIDS and sexually transmitted dis-
eases; 
(11) uterine fibroids; 
(12) autoimmune disease; 
(13) mental health conditions; 
(14) dental health conditions and oral diseases, 
including oral cancer; 
(15) environmental and related health illnesses 
and conditions; 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00475
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
476 
(16) Sickle cell disease; 
(17) violence and injury prevention and control; 
(18) genetic and related conditions; 
(19) heart disease and stroke; 
(20) tuberculosis; 
(21) chronic obstructive pulmonary disease; 
(22) musculoskeletal diseases, arthritis, and 
obesity; and 
(23) other diseases determined appropriate by 
the Secretary. 
(d) DISSEMINATION.—Not later than 24 months 
after the date of enactment of this title, the Secretary 
shall publish and disseminate to health care provider orga-
nizations the guidelines developed under subsection (a). 
(e) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section, 
such sums as may be necessary for each of fiscal years 
2015 through 2019. 
SEC. 732. CDC WISEWOMAN SCREENING PROGRAM. 
Section 1509 of the Public Health Service Act (42 
U.S.C. 300n–4a) is amended— 
(1) in subsection (a)— 
(A) by striking the heading and inserting 
‘‘IN GENERAL.—’’; and 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00476
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
477 
(B) in the matter preceding paragraph (1), 
by striking ‘‘may make grants’’ and all that fol-
lows through ‘‘purpose’’ and inserting the fol-
lowing: ‘‘may make grants to such States for 
the purpose’’; and 
(2) in subsection (d)(1), by striking ‘‘there are 
authorized’’ and all that follows through the period 
and inserting ‘‘there are authorized to be appro-
priated 
$23,000,000 
for 
fiscal 
year 
2015, 
$25,300,000 for fiscal year 2016, $27,800,000 for 
fiscal year 2017, $30,800,000 for fiscal year 2018, 
and $34,000,000 for fiscal year 2019.’’. 
SEC. 733. REPORT ON CARDIOVASCULAR CARE FOR WOMEN 
AND MINORITIES. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 399V–6. REPORT ON CARDIOVASCULAR CARE FOR 
WOMEN AND MINORITIES. 
‘‘Not later than September 30, 2015, and annually 
thereafter, the Secretary shall prepare and submit to the 
Congress a report on the quality of and access to care 
for women and minorities with heart disease, stroke, and 
other cardiovascular diseases. The report shall contain rec-
ommendations for eliminating disparities in, and improv-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00477
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
478 
ing the treatment of, heart disease, stroke, and other car-
diovascular diseases in women, racial and ethnic minori-
ties, those for whom English is not their primary lan-
guage, and individuals with disabilities.’’. 
SEC. 734. COVERAGE OF COMPREHENSIVE TOBACCO CES-
SATION SERVICES IN MEDICAID. 
(a) REQUIRING COVERAGE
OF COUNSELING
AND 
PHARMACOTHERAPY
FOR
CESSATION
OF
TOBACCO 
USE.—Section 1905 of the Social Security Act (42 U.S.C. 
1396d) is amended— 
(1) in subsection (a)(4)(D) is amended by strik-
ing ‘‘by pregnant women’’; and 
(2) in subsection (bb)— 
(A) by striking ‘‘by pregnant women’’ each 
place it appears; 
(B) in paragraph (1), in the matter before 
subparagraph (A), by inserting ‘‘by individuals’’ 
before ‘‘who use tobacco’’; and 
(C) in paragraph (2)(A), by striking ‘‘with 
respect to pregnant women’’. 
(b) EXCEPTION
FROM
OPTIONAL
RESTRICTION 
UNDER MEDICAID PRESCRIPTION DRUG COVERAGE.— 
Section 1927(d)(2)(F) of the Social Security Act (42 
U.S.C. 1396r–8(d)(2)(F)) is amended by striking ‘‘in the 
case of pregnant women’’. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00478
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
479 
(c) REMOVAL OF COST SHARING FOR COUNSELING 
AND PHARMACOTHERAPY FOR CESSATION OF TOBACCO 
USE.— 
(1) GENERAL COST SHARING LIMITATIONS.— 
Section 1916 of the Social Security Act (42 U.S.C. 
1396o) is amended— 
(A) in subsections (a)(2)(B) and (b)(2)(B), 
by 
striking 
‘‘and 
counseling 
and 
pharmacotherapy for cessation of tobacco use 
by pregnant women (as defined in section 
1905(bb)) and covered outpatient drugs (as de-
fined in subsection (k)(2) of section 1927 and 
including nonprescription drugs described in 
subsection (d)(2) of such section) that are pre-
scribed for purposes of promoting, and when 
used to promote, tobacco cessation by pregnant 
women in accordance with the Guideline re-
ferred to in section 1905(bb)(2)(A)’’ each place 
it appears; and 
(B) in each of subsections (a)(2)(D) and 
(b)(2)(D) by inserting ‘‘and counseling and 
pharmacotherapy for cessation of tobacco use 
(as defined in section 1905(bb)) and covered 
outpatient drugs (as defined in subsection 
(k)(2) of section 1927 and including non-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00479
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
480 
prescription drugs described in subsection 
(d)(2) of such section) that are prescribed for 
purposes of promoting, and when used to pro-
mote, tobacco cessation in accordance with the 
Guideline 
referred 
to 
in 
section 
1905(bb)(2)(A),’’ 
after 
‘‘section 
1905(a)(4)(C),’’. 
(2) APPLICATION TO ALTERNATIVE COST SHAR-
ING.—Section 1916A(b)(3)(B) of such Act (42 
U.S.C. 
1396o–1(b)(3)(B)42 
U.S.C. 
1396o– 
1(b)(3)(B)) is amended— 
(A) in clause (iii), by striking ‘‘, and coun-
seling and pharmacotherapy for cessation of to-
bacco use by pregnant women (as defined in 
section 1905(bb))’’; and 
(B) by adding at the end the following: 
‘‘(xi) Counseling and pharmacothera-
py for cessation of tobacco use (as defined 
in section 1905(bb)) and covered out-
patient drugs (as defined in subsection 
(k)(2) of section 1927 and including non-
prescription drugs described in subsection 
(d)(2) of such section) that are prescribed 
for purposes of promoting, and when used 
to promote, tobacco cessation in accord-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00480
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
481 
ance with the Guideline referred to in sec-
tion 1905(bb)(2)(A).’’. 
(d) EFFECTIVE DATE.—The amendments made by 
this section shall take effect on October 1, 2014. 
SEC. 
735. 
CLINICAL 
RESEARCH 
FUNDING 
FOR 
ORAL 
HEALTH. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall expand and intensify the conduct 
and support of the research activities of the National In-
stitutes of Health and the National Institute of Dental 
and Craniofacial Research to improve the oral health of 
the population through the prevention and management 
of oral diseases and conditions. 
(b) INCLUDED RESEARCH ACTIVITIES.—Research 
activities under subsection (a) shall include— 
(1) comparative effectiveness research and clin-
ical disease management research addressing early 
childhood caries and oral cancer; and 
(2) awarding of grants and contracts to support 
the training and development of health services re-
searchers, comparative effectiveness researchers, and 
clinical researchers whose research improves the oral 
health of the population. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00481
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
482 
SEC. 736. PARTICIPATION BY MEDICAID BENEFICIARIES IN 
APPROVED CLINICAL TRIALS. 
(a) IN GENERAL.—Title XIX of the Social Security 
Act (42 U.S.C. 1396 et seq.) is amended by inserting after 
section 1943 the following new section: 
‘‘SEC. 1944. PARTICIPATION IN AN APPROVED CLINICAL 
TRIAL. 
‘‘(a) COVERAGE OF ROUTINE PATIENT COSTS ASSO-
CIATED WITH APPROVED CLINICAL TRIALS.— 
‘‘(1) INCLUSION.—Subject to paragraph (2), 
routine patient costs shall include all items and serv-
ices consistent with the medical assistance provided 
under the State plan that would otherwise be pro-
vided to the individual under such State plan if such 
individual was not enrolled in an approved clinical 
trial, including any items or services related to the 
prevention, detection, and treatment of any medical 
complications that arise as a result of participation 
in the approved clinical trial. 
‘‘(2) EXCLUSION.—For purposes of paragraph 
(1), routine patient costs does not include— 
‘‘(A) the investigational item, device, or 
service itself; 
‘‘(B) items and services that are provided 
solely to satisfy data collection and analysis 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00482
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
483 
needs and that are not used in the direct clin-
ical management of the patient; or 
‘‘(C) a service that is clearly inconsistent 
with widely accepted and established standards 
of care for a particular diagnosis. 
‘‘(3) 
INFORMATION
CONCERNING
CLINICAL 
TRIALS.— 
‘‘(A) IN
GENERAL.—Subject to subpara-
graph (B), the Secretary, in consultation with 
relevant stakeholders, shall develop a single 
standardized electronic form for use by the indi-
vidual or the referring health care provider to 
submit to the State agency administering the 
State plan in order to verify that the clinical 
trial meets the conditions established for an ap-
proved clinical trial (as defined in subsection 
(c)). 
‘‘(B) EXCLUDED INFORMATION.—For pur-
poses of subparagraph (A) or any such request 
by the State agency for information regarding 
a clinical trial, an individual or referring health 
care provider shall not be required to submit— 
‘‘(i) the clinical protocol document for 
the clinical trial; or 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00483
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
484 
‘‘(ii) subject to subparagraph (C), any 
additional information other than such in-
formation as is required pursuant to the 
form described in subparagraph (A). 
‘‘(C) OPTIONAL INFORMATION.—For pur-
poses of subparagraphs (A) and (B)(ii), the 
form may include a requirement that the refer-
ring health care provider attest that the indi-
vidual is eligible to participate in the clinical 
trial pursuant to the trial protocol and that 
their participation in such trial would be appro-
priate. 
‘‘(D) REVIEW OF INFORMATION.— 
‘‘(i) IN
GENERAL.—A State plan 
under this title shall establish a process for 
timely review by the State agency of the 
form and information submitted pursuant 
to subparagraph (A) and, not later than 
48 hours after receipt of such form, con-
firmation that the information provided in 
such form satisfies the requirements estab-
lished under such subparagraph, with such 
process to include establishment and oper-
ation of a 24-hour, toll-free telephone num-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00484
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
485 
ber and e-mail address to provide for expe-
dited communication. 
‘‘(ii) FAILURE
TO
RESPOND.—If an 
individual or the referring health care pro-
vider does not receive a response or re-
quest for additional information from the 
State agency following the 48-hour period 
described in clause (i), the information 
provided in the form may be presumed to 
satisfy the requirements established under 
this paragraph. 
‘‘(b) ENCOURAGEMENT OF PARTICIPATION IN AP-
PROVED CLINICAL TRIALS.— 
‘‘(1) REASONABLY
ACCESSIBLE
PROVIDER.— 
For purposes of participation in an approved clinical 
trial by an individual eligible for medical assistance 
under this title, the State agency administering the 
State plan shall make reasonable efforts to ensure 
that the individual is provided with access to a pro-
vider who is— 
‘‘(A) participating in the approved clinical 
trial; 
‘‘(B) located not more than 25 miles from 
the residence of the individual (or, if no such 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00485
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
486 
provider is available, as close as possible to the 
residence of the individual); and 
‘‘(C) a participating provider under the 
State plan or has been deemed to be a partici-
pating provider under the State plan for pur-
poses of providing medical assistance to the in-
dividual during their participation in the ap-
proved clinical trial. 
‘‘(2) INFORMATIONAL MATERIALS.—The State 
agency administering the plan approved under this 
title shall develop informational materials and pro-
grams to encourage participating providers to make 
appropriate referrals to physicians and other appro-
priate health care professionals who can provide in-
dividuals with access to approved clinical trials. 
‘‘(c) DEFINITION OF APPROVED CLINICAL TRIAL.— 
The term ‘approved clinical trial’ has the same meaning 
as provided under section 2709(d) of the Public Health 
Service Act.’’. 
(b) CONFORMING AMENDMENT.—Section 1902(a) of 
such Act (42 U.S.C. 1396a(a)) is amended by inserting 
after paragraph (77) the following new paragraph: 
‘‘(78) provide that participation in an approved 
clinical trial and coverage of routine patient costs 
associated with such trial for an individual eligible 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00486
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
487 
for medical assistance under this title is conducted 
in accordance with the requirements under section 
1944;’’. 
(c) EFFECTIVE DATE.— 
(1) IN GENERAL.—Except as provided in para-
graph (2), the amendments made by this section 
shall apply to calendar quarters beginning on or 
after October 1, 2014. 
(2) DELAY
PERMITTED
FOR
STATE
PLAN 
AMENDMENT.—In the case of a State plan for med-
ical assistance under title XIX of the Social Security 
Act which the Secretary of Health and Human Serv-
ices determines requires State legislation (other than 
legislation appropriating funds) in order for the plan 
to meet the additional requirements imposed by the 
amendments made by this section, the State plan 
shall not be regarded as failing to comply with the 
requirements of such title solely on the basis of its 
failure to meet these additional requirements before 
the first day of the first calendar quarter beginning 
after the close of the first regular session of the 
State legislature that begins after the date of enact-
ment of this Act. For purposes of the previous sen-
tence, in the case of a State that has a 2-year legis-
lative session, each year of such session shall be 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00487
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
488 
deemed to be a separate regular session of the State 
legislature. 
Subtitle E—HIV/AIDS 
SEC. 741. STATEMENT OF POLICY. 
It is the policy of the United States to achieve an 
AIDS-free generation, and to— 
(1) expand access to lifesaving antiretroviral 
therapy for people living with HIV/AIDS and imme-
diately link people to continuous and coordinated 
high-quality care when they learn they are infected 
with HIV; 
(2) expand targeted efforts to prevent HIV in-
fection using a combination of effective, evidence- 
based approaches, including routine HIV screening, 
and universal access to HIV prevention tools in the 
communities where HIV/AIDS is most heavily con-
centrated, particularly communities of color; 
(3) ensure laws, policies, and regulations do not 
impede access to prevention, treatment, and care for 
people living with HIV/AIDS or at risk for acquiring 
HIV; 
(4) accelerate research for more efficacious HIV 
prevention and treatments tools, a cure, and a vac-
cine; and 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00488
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
489 
(5) respect the human rights and dignity of 
persons living with HIV/AIDS. 
SEC. 742. FINDINGS. 
The Congress finds the following: 
(1) Over one million people are estimated to be 
living with HIV in the United States according to 
the Centers for Disease Control and Prevention, 18 
percent of whom are unaware of their HIV-positive 
status. 
(2) Annually there are over 50,000 new HIV in-
fections and 20,000 deaths in people with an HIV 
diagnoses in 50 States and 6 dependent areas of the 
United States. 
(3) The Centers for Disease Control and Pre-
vention estimates that in 2011 there were approxi-
mately 50,199 people newly diagnosed with HIV. 
Though this number seems to be staying relatively 
stable, the number of new infections is rapidly in-
creasing among certain populations especially among 
young African-American men who have sex with men 
(MSM) who, in 2010, accounted for 45 percent of 
new HIV infections among black MSM and 55 per-
cent of HIV infections among young MSM overall. 
(4) HIV disproportionately affects certain popu-
lations in the United States. Though African-Ameri-
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00489
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
490 
cans represent less than 13 percent of the popu-
lation, African-Americans account for almost half 
(44 percent) of all people living with HIV in the 
United States. Men who have sex with men (MSM) 
make up approximately 4 percent of the population, 
but account for 63 percent of all new HIV infections 
and are the only risk group in which HIV infections 
continue to increase. 
(5) Disparities exist among Latinos/Hispanics; 
they make up 16 percent of US population and 22 
percent of new infections (2011). 
(6) Though American Indians/Alaska Natives 
represent less than 2 percent of the total number of 
HIV/AIDS cases, American Indians and Alaska Na-
tives rank fifth in rates of HIV/AIDS diagnosis, still 
higher than their White counterparts. 
(7) While Asian-Americans, Native Hawaiians, 
and Pacific Islanders HIV/AIDS cases account for 
approximately 1 percent of cases nationally, between 
2010 and 2011, the rate of new HIV diagnoses in-
creased for Asian-Americans by 22 percent. 
(8) The latest data from the CDC (2013) indi-
cate that women account for 1 in 5 (20 percent) new 
HIV infections in the United States women of color, 
particularly Black women, have been especially hard 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00490
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
491 
hit and represent the majority of women living with 
the disease and women newly infected. In addition, 
Black women accounted for nearly two-thirds (64 
percent) of all estimated new HIV infections among 
women, while only accounting for 13 percent of the 
female population; White women accounted for 18 
percent and Latinas 15 percent of new infections. 
(9) The history of HIV shows that culturally 
relevant and gender-responsive supportive services, 
including psychosocial support, treatment literacy, 
case management, and transportation are necessary 
strategies to reach and engage women and girls in 
medical care. 
(10) The limited data available on transgender 
individuals point to a disproportionate burden of 
HIV infection. 
(11) Stigma and discrimination contribute to 
these disparities. 
(12) The Centers for Disease Control and Pre-
vention has determined that increasing the propor-
tion of people who know their HIV status is an es-
sential component of comprehensive HIV/AIDS 
treatment and prevention efforts and that early di-
agnosis is critical in order for people with HIV/ 
AIDS to receive life-extending therapy. Additionally, 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00491
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
492 
the Centers for Disease Control and Prevention rec-
ommend routine HIV screening in health care set-
tings for all patients aged 13 to 64, regardless of 
risk. 
(13) In 1998, Congress created the National 
Minority AIDS Initiative to provide technical assist-
ance, build capacity, and strengthen outreach efforts 
among local institutions and community-based orga-
nizations that serve racial and ethnic minorities liv-
ing with or vulnerable to HIV/AIDS. 
(14) To combat the HIV epidemic in the United 
States, the National HIV/AIDS Strategy (NHAS) 
from the White House Office of National AIDS Pol-
icy provides a framework of increasing access to 
care, reducing new infections, and eliminating HIV- 
related health disparities. The vision of NHAS is 
‘‘The United States will become a place where new 
HIV infections are rare and when they do occur, 
every person, regardless of age, gender, race/eth-
nicity, 
gender 
identity, 
or 
socioeconomic 
cir-
cumstance, will have unfettered access to high qual-
ity, life-extending care, free from stigma and dis-
crimination.’’. 
(15) In recent years, several thousand people 
across the country were waiting to receive AIDS 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00492
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
493 
treatment through the AIDS Drug Assistance Pro-
gram authorized by the provisions popularly known 
as the Ryan White CARE Act. 
(16) At present, 34 States and 2 United States 
territories have criminal statutes based on ‘‘expo-
sure’’ to HIV. Most of these laws were adopted be-
fore the availability of effective antiretroviral treat-
ment for HIV/AIDS. 
(17) Although the cost of education, treatment 
and care, and research are not inconsequential, they 
are substantially less than the annual health care 
cost attributable to HIV in the United States. The 
lifetime cost of HIV care and treatment in 2004 was 
estimated to be $405,000 to $648,000 annually. 
Preventing 40,000 new infections in the United 
States each year would save $12.8 billion annually. 
(18) According to the Centers for Disease Con-
trol and Prevention (CDC), latex condoms, when 
used consistently and correctly, are highly effective 
in preventing the transmission of HIV. Latex 
condoms also reduce the risk of other STIs. Despite 
the effectiveness of condoms in reducing the spread 
of STIs, the Bureau of Prisons does not recommend 
their use in correctional facilities. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00493
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
494 
(19) The distribution of condoms in correctional 
facilities is currently legal in certain parts of the 
United States and the world. The States of Vermont 
and Mississippi, the District of Columbia, and the 
cities of New York, San Francisco, Los Angeles, 
Washington, DC, and Philadelphia allow condom 
distribution in their correctional facilities. However, 
these States and cities operate fewer than 1 percent 
of all correctional facilities. 
(20) Many correctional facilities in the United 
States do not provide comprehensive testing and 
treatment programs to reduce the spread of STIs. 
Fewer than half of correctional facilities provide 
counseling to HIV-positive incarcerated persons. 
(21) Incarcerated individuals living with HIV/ 
AIDS who are eligible for Medicaid would benefit 
from prompt and automatic enrollment upon their 
release in order to ensure their continued ability to 
access health services, including antiretroviral treat-
ment. 
(22) Research shows that stable housing leads 
to better health outcomes for those living with HIV. 
Inadequate or unstable housing is not only a barrier 
to effective treatment, but also increases the likeli-
hood of engaging in risky behaviors leading to HIV 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00494
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
495 
infection. Insecure housing puts people with HIV/ 
AIDS at risk of premature death from exposure to 
other diseases, poor nutrition, and lack of medical 
care. 
(23) Due to advances in treatment, many peo-
ple living with HIV/AIDS (PLWHA) today are liv-
ing healthy lives and have the ability and desire to 
fully participate in all aspects of community life, in-
cluding employment. Research associates being em-
ployed with tremendous economic, social, and health 
benefits for many people living with HIV/AIDS. 
(24) The common benefits associated with em-
ployment include income, autonomy, productivity, 
and status within society, daily structure, making a 
contribution to one’s community, and increased skills 
and self-esteem. Research also indicates that many 
people with disabilities, including PLWHA, report 
perceiving themselves as being less disabled or not 
disabled at all, when working. Furthermore, some 
studies link working with better physical and mental 
health outcomes for PLWHA when compared to 
those who are not working. Preliminary data also 
suggest that transitioning to employment is associ-
ated with reduced HIV-related health risk behavior 
for many people. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00495
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
496 
(25) On July 16, 2012, the Food and Drug Ad-
ministration approved the first drug to reduce the 
risk of HIV infection in uninfected individuals who 
are at high risk of HIV infection and who may en-
gage in sexual activity with HIV-infected partners. 
SEC. 743. ADDITIONAL FUNDING FOR AIDS DRUG ASSIST-
ANCE PROGRAM TREATMENTS. 
Section 2623 of the Public Health Service Act (42 
U.S.C. 300ff–31b) is amended by adding at the end the 
following: 
‘‘(c) ADDITIONAL FUNDING FOR AIDS DRUG AS-
SISTANCE
PROGRAM
TREATMENTS.—In addition to 
amounts otherwise authorized to be appropriated for car-
rying out this subpart, there are authorized to be appro-
priated such sums as may be necessary to carry out sec-
tions 2612(b)(3)(B) and 2616 for each of fiscal years 
2015 through 2017.’’. 
SEC. 744. ENHANCING THE NATIONAL HIV SURVEILLANCE 
SYSTEM. 
(a) GRANTS.—The Secretary of Health and Human 
Services, acting through the Director of the Centers for 
Disease Control and Prevention, shall make grants to 
States to support integration of public health surveillance 
systems into all electronic health records in order to allow 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00496
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
497 
rapid communications between the clinical setting and 
health departments, by means that include— 
(1) providing technical assistance and policy 
guidance to State and local health departments, clin-
ical providers, and other agencies serving individuals 
with HIV to improve the interoperability of data sys-
tems relevant to monitoring HIV care and sup-
portive services; 
(2) capturing longitudinal data pertaining to 
the initiation and ongoing prescription or dispensing 
of antiretroviral therapy for individuals diagnosed 
with HIV (such as through pharmacy-based report-
ing); 
(3) obtaining information— 
(A) on a voluntary basis, on sexual orienta-
tion and gender identity; and 
(B) on sources of coverage (or the lack 
thereof) for medical treatment (including cov-
erage through Medicaid, Medicare, the program 
under title XXVI of the Public Health Service 
Act (42 U.S.C. 300ff–11 et seq.; commonly re-
ferred to as the ‘‘Ryan White HIV/AIDS Pro-
gram’’), other public funding, private insurance, 
and health maintenance organizations); and 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00497
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
498 
(4) obtaining and using current geographic 
markers of residence (such as current address, zip 
code, partial zip code, and census block). 
(b) PRIVACY AND SECURITY SAFEGUARDS.—In car-
rying out this section, the Secretary of Health and Human 
Services shall ensure that appropriate privacy and security 
safeguards are met to prevent unauthorized disclosure of 
protected health information and compliance with the 
HIPAA privacy and security law (as defined in section 
3009 of the Public Health Service Act (42 U.S.C. 300jj– 
19)) and other relevant laws and regulations. 
(c) PROHIBITION
AGAINST
IMPROPER
USE
OF 
DATA.—No grant under this section may be used to allow 
or facilitate the collection or use of surveillance or clinical 
data or records— 
(1) for punitive measures of any kind, civil or 
criminal, against the subject of such data or records; 
or 
(2) for imposing any requirement or restriction 
with respect to an individual without the individual’s 
written consent. 
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for each of fiscal years 
2015 through 2019. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00498
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
499 
SEC. 745. EVIDENCE-BASED STRATEGIES FOR IMPROVING 
LINKAGE TO AND RETENTION IN APPRO-
PRIATE CARE. 
(a) STRATEGIES.—The Secretary of Health and 
Human Services, in collaboration with the Director of the 
Centers for Disease Control and Prevention, the Adminis-
trator of the Substance Abuse and Mental Health Services 
Administration, the Director of the Office of AIDS Re-
search, the Administrator of the Health Resources and 
Services Administration, and the Administrator of the 
Centers for Medicare & Medicaid Services, shall— 
(1) identify evidence-based strategies most ef-
fective at addressing the multifaceted issues that im-
pede disease status awareness and linkage to and re-
tention in appropriate care, taking into consideration 
health care systems issues, clinic and provider 
issues, and individual psychosocial, environmental, 
and other contextual factors; 
(2) support the wide-scale implementation of 
the evidence-based strategies identified pursuant to 
paragraph (1), including through incorporating such 
strategies into health care coverage supported by the 
Medicaid program under title XIX of the Social Se-
curity Act (42 U.S.C. 1396 et seq.), the program 
under title XXVI of the Public Health Service Act 
(42 U.S.C. 300ff–11 et seq.; commonly referred to 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00499
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
500 
as the ‘‘Ryan White HIV/AIDS Program’’), and 
health plans purchased through an American Health 
Benefit Exchange established pursuant to section 
1311 of the Patient Protection and Affordable Care 
Act (42 U.S.C. 18031); and 
(3) not later than 12 months after the date of 
the enactment of this Act, submit a report to the 
Congress on the status of activities under para-
graphs (1) and (2). 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2015 
through 2019. 
SEC. 746. IMPROVING ENTRY INTO AND RETENTION IN 
CARE AND ANTIRETROVIRAL ADHERENCE 
FOR PERSONS WITH HIV. 
(a) SENSE OF CONGRESS.—It is the sense of the Con-
gress that AIDS research has led to scientific advance-
ments that have— 
(1) saved the lives of millions of people with 
HIV/AIDS; 
(2) prevented millions of people from being in-
fected; and 
(3) had broad benefits that extend far beyond 
helping people at risk for or living with HIV. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00500
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
501 
(b) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Director of the Na-
tional Institutes of Health, shall expand, intensify, and co-
ordinate operational and translational research and other 
activities of the National Institutes of Health regarding 
methods— 
(1) to increase adoption of evidence-based ad-
herence strategies within HIV care and treatment 
programs; 
(2) to increase HIV testing and case detection 
rates; 
(3) to reduce HIV-related health disparities; 
(4) to ensure that research to improve adher-
ence to HIV care and treatment programs address 
the unique concerns of women; 
(5) to integrate HIV/AIDS prevention and care 
services with mental health and substance use pre-
vention and treatment delivery systems; and 
(6) to increase knowledge on the implementa-
tion of preexposure prophylaxis (PrEP), including 
with respect to— 
(A) who can benefit most from PrEP; 
(B) how to provide PrEP safely and effi-
ciently; 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00501
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
502 
(C) how to integrate PrEP with other es-
sential prevention methods such as condoms; 
and 
(D) how to ensure high levels of adherence. 
(c) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
such sums as may be necessary for fiscal years 2015 
through 2019. 
SEC. 747. SERVICES TO REDUCE HIV/AIDS IN RACIAL AND 
ETHNIC MINORITY COMMUNITIES. 
(a) IN GENERAL.—For the purpose of reducing HIV/ 
AIDS in racial and ethnic minority communities, the Sec-
retary, acting through the Deputy Assistant Secretary for 
Minority Health, may make grants to public health agen-
cies and faith-based organizations to conduct— 
(1) outreach activities related to HIV/AIDS 
prevention and testing activities; 
(2) HIV/AIDS prevention activities; and 
(3) HIV/AIDS testing activities. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
$50,000,000 for fiscal year 2015, and such sums as may 
be necessary for fiscal years 2016 through 2019. 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00502
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
503 
SEC. 748. MINORITY AIDS INITIATIVE. 
(a) EXPANDED FUNDING.—The Secretary, in col-
laboration with the Deputy Assistant Secretary for Minor-
ity Health, the Director of the Centers for Disease Control 
and Prevention, the Administrator of the Health Re-
sources and Services Administration, and the Adminis-
trator of the Substance Abuse and Mental Health Services 
Administration, shall provide funds and carry out activi-
ties to expand the Minority HIV/AIDS Initiative. 
(b) USE OF FUNDS.—The additional funds made 
available under this section may be used, through the Mi-
nority AIDS Initiative, to support the following activities: 
(1) Providing technical assistance and infra-
structure support to reduce HIV/AIDS in minority 
populations. 
(2) Increasing minority populations’ access to 
HIV/AIDS prevention and care services. 
(3) Building strong community programs and 
partnerships to address HIV prevention and the 
health care needs of specific racial and ethnic minor-
ity populations. 
(c) PRIORITY INTERVENTIONS.—Within the racial 
and ethnic minority populations referred to in subsection 
(b), priority in conducting intervention services shall be 
given to— 
(1) men who have sex with men; 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00503
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS
522 
(i) SELECTION OF EVALUATED PRO-
GRAMS.—The Secretary shall select, at 
random, a subset of the eligible entities 
that the Secretary has selected to receive a 
grant under this subsection to receive addi-
tional funding to carry out the evaluation 
plan described in subparagraph (A). 
(ii) BUDGET FOR EVALUATION ACTIVI-
TIES.—The Secretary, in coordination with 
the Director of the Office of Adolescent 
Health, shall establish a budget for each 
eligible entity selected under clause (i) for 
the costs of carrying out the evaluation 
plan described in subparagraph (A). 
(C) FUNDS FOR EVALUATION.—The Sec-
retary shall provide eligible entities who are se-
lected under subparagraph (B)(i) with addi-
tional funds, in accordance with the budget de-
scribed in subparagraph (B)(ii), to carry out 
and report to the Secretary on the evaluation 
plan described in subparagraph (A). 
(D) PERFORMANCE MEASURES.—The Sec-
retary, in coordination with the Director of the 
Centers for Disease Control and Prevention, 
shall establish a common set of performance 
VerDate Mar 15 2010 
23:38 Aug 05, 2014
Jkt 039200
PO 00000
Frm 00522
Fmt 6652
Sfmt 6201
E:\BILLS\H5294.IH
H5294
smartinez on DSK4TPTVN1PROD with BILLS